Navigation Links
Shimadzu and EDDA Announce Business Partnership on X-ray Chest CAD Applications
Date:11/11/2009

KYOTO, Japan and PRINCETON, N.J., Nov. 11 /PRNewswire/ -- Shimadzu Corporation (Kyoto Japan) and EDDA Technology Inc. (Princeton, NJ, USA) today announced that both parties have entered into a business partnership on X-ray chest CAD systems based on the Radiography System of Shimadzu featuring its direct conversion flat panel detector (FPD) and EDDA's CAD applications.

This partnership contains both distribution of EDDA's chest X-ray CAD applications with Shimadzu's DR system through Shimadzu's worldwide sales channel and the development of fully new applications integrating Shimadzu's state-of-the-art application for digital radiography together with EDDA's sophisticated technology in the field of chest CAD.

Chest X-ray CAD (Computer Aided Detection) is an advanced clinical application aiming the improvement of physician's detection accuracy of lung nodules by identifying possible nodules efficiently using computer image analysis technology, which will also help to overcome the challenge of workload of physicians in the diagnosis process. Chest X-ray is the most commonly performed radiographic exam accounting for nearly 50% of all imaging tests, and over 70 million chest X-rays are performed yearly in the US.

EDDA is a pioneer in the area of chest CAD application. Its IQQA®-Chest CAD product is already approved by FDA, EU CE and China SFDA, and is sold and used in USA, Europe, China and other countries. The first prospective study on chest X-ray CAD published in peer-reviewed journal showed positive results that suggest the interpretation of chest radiographs for lung nodules can be improved using IQQA®-Chest. Shimadzu will distribute this chest X-ray CAD application with its DR products in worldwide markets (*). Both companies are working together to prepare another innovative new chest CAD application which shall be introduced to worldwide markets in the upcoming years.

"According to the statistics such as those from WHO, ratio of death from cancer in the recent years tends to be decreasing. However, that from lung cancer is remarkably increasing, " said Mr. Kunimasa Itoh, general manager, marketing dept., medical systems division of Shimadzu Corporation. "Through the partnership with EDDA, who is expert of application development in this field, we will be able to contribute to improving clinical workflow and quality care of patients by providing advanced image diagnosis solutions to aid in early detection of lung lesions."

"Our partnership with Shimadzu Corporation reflects the increasingly important role that advanced computer application plays in enhancing clinical workflow to be faster, better and more cost-effective," said Dr. Jian-Zhong Qian, president and CEO of EDDA Technology. "We are pleased to partner with Shimadzu to offer new solutions to the diagnosis and management of potentially life-threatening lung diseases."

(* Regulatory approval for the distribution through Shimadzu in Japan and other countries are pending as of this moment.)

About Shimadzu Corporation

Founded in 1875, Shimadzu Corporation, a leader in the development of advanced technologies, has a distinguished history of innovation build on the foundation of contributing to society through science and technology. Shimadzu maintain a global network of sales, service, technical support and applications centers on six continents, and have established long-term relationship with a host of highly trained distributors located in over 100 countries.

About EDDA Technology

EDDA Technology, Inc. is an innovative clinical computer solution provider in diagnostic imaging and analysis. EDDA offers a series of new generation software products to enable early detection of diseases, and enhance efficiency and precision in diagnosis and treatment. EDDA's goal is to deliver, with broad accessibility, advanced information analysis technologies that improve clinical workflow and accuracy. A privately held Delaware corporation, EDDA is headquartered in Princeton, New Jersey, and has a subsidiary in Shanghai, China. IQQA is a registered trademark of EDDA Technology.

Editor's Note: EDDA Technology will be exhibiting in Booth # 9318, and Shimadzu Corporation in Booth #5000, of McCormick Place in Chicago at the 95th Scientific Assembly and Annual Meeting of the Radiological Society of North America (RSNA), Nov. 29 - Dec. 3, 2009.

SOURCE Edda Technology, Inc.


'/>"/>
SOURCE Edda Technology, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
5. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
6. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
7. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
8. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
9. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
10. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
11. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... , Dec. 8, 2016  Valeant Pharmaceuticals ... TSX: VRX) ("Valeant") today announced positive results from ... study to assess the safety and efficacy of ... treatment of plaque psoriasis. Within ... with moderate to severe psoriasis, IDP-118 showed statistical ...
(Date:12/8/2016)... Mederi Therapeutics Inc . hat die behördliche Zulassung durch ... gastroösophageale Refluxerkrankung (GERD) – in China angekündigt. ... ... Live Stretta procedure performed and broadcast during ... Endoscopy at Wuhan Union Hospital ...
(Date:12/8/2016)...  Boehringer Ingelheim announced today that it has been ... is the ninth time that the company received a ... Place to Work for LGBT Equality. Administered by the ... benchmarking report on corporate policies and practices related to ... employees. "We are committed to creating ...
Breaking Medicine Technology:
(Date:12/8/2016)... ... 08, 2016 , ... California Senate Bill (SB) 863, signed into law in ... 2013 and 2014, according to CompScope™ Medical Benchmarks for California, 17th Edition , ... the study, medical payments per claim in California decreased 4 percent in 2013 and ...
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... ... and financial planning services from offices headquartered in Hamilton County, is embarking on ... LuvFurMutts. , LuvFurMutts specializes in finding new homes for orphaned or neglected senior ...
(Date:12/8/2016)... ... December 08, 2016 , ... Coffey Agencies, a ... and commercial clients in the northern Alabama and Georgia regions, is embarking on ... 1977, Nobis Works has built a network of support and education facilities to ...
(Date:12/7/2016)... ... 2016 , ... Kenall Manufacturing, a leader in sealed healthcare lighting for more ... a multi-function, sealed, LED luminaire that meets the needs of everyone in the patient ... , A 2’ x 4’ model features four modes: reading, ambient, standard ...
(Date:12/7/2016)... ... December 07, 2016 , ... ... S.L. (“Presence”) for a purchase price of approximately $17.4 million (net of ... annual revenue is approximately $13.2 million. Headquartered in Barcelona, Spain, Presence is ...
Breaking Medicine News(10 mins):